Organon delivers impactful medicines and solutions for a healthier every day
We are a different kind of healthcare company. We envision a better and healthier every day for every woman. By addressing health conditions that are unique to women, affect her disproportionately or impact her differently, we are igniting our purpose to advance the complete health of women at all stages of her life journey.
Our global business is comprised of three core pillars: women’s health, biosimilars, and established brands. Our diverse global portfolio consists of over 60 products across a range of areas including reproductive health, cardiovascular disease, neurology, autoimmune and respiratory conditions. And we bring these important medicines around the world, with an international footprint that serves people in more than 140 markets.
Women’s Health
We are fearless in our aim to deliver innovation, improve access, and expand choice to help address therapeutic gaps in women’s health. Our global expertise is in reproductive health, with a focus on contraception and fertility and a commitment to expand into areas that address other diseases and conditions that impact her health throughout her life.
Beyond our product offerings, access to our medicines is equally important. As we work to reach more women around the world, we are also dedicated to ensuring that she has access to our treatments.
Organon’s global portfolio and innovation pipeline are focused on these key areas:
• bacterial vaginosis (BV)
• breast cancer
• contraception
• endometriosis
• fertility
• hysterectomy
• menopause
• osteoporosis
• polycystic ovarian syndrome (PCOS)
• postpartum haemorrhage (PPH)
Established Brands
These brands embody early innovation and deep heritage. With a long history across serious diseases and conditions and even after loss of exclusivity for some of these products, they continue to have an impact around world.
Combined with our strong manufacturing capabilities and broad geographic footprint, we will continue delivering on the full potential of our established brands portfolio by seizing new opportunities to bring these important treatments to people who need them through indication expansions and collaborations.
Our global portfolio of 49 medicines spans several areas:
• cardiovascular disease (CVD)
• respiratory conditions
• dermatology
• central nervous system (CNS) disorders
• bone health
• immunology
• non-opioid pain management
• menopause
Biosimilars
We believe that biosimilars are an important option that can help reduce the cost pressure on the healthcare system whilst helping more patients access biologic therapies. Our biosimilars products are available in various parts of the world and treat a variety of serious diseases and conditions. Organon’s expertise is in the commercialisation of these products, providing high-quality biosimilar medicines to health care systems, providers, and patients.
Helping navigate the complexities of biosimilar adoption is at the core of our commitment to enable the many potential benefits of biosimilars across the health care system. As the biosimilar landscape changes, we adapt— expanding our offerings through new collaborations and into new disease areas while maintaining an unwavering commitment to patients and providers.
